The acquisition of Ambry Genetics strengthens Tempus AI's genomics capabilities by adding a West Coast lab and expanding ...

We recently published a list of 10 AI Stocks on Analysts’ Radar As AI Spending Grows. In this article, we are going to take a ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results, presenting a buying ...

Tempus AI (TEM) reports Q4 earnings Monday, expected loss of 20 cents/share, $203.12M in revenues. Stock up 98.80% YTD.

Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and ...

Reports Q4 revenue $200.7M, consensus $202.8M. “Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to ...

Q4 2024 Earnings Call Transcript February 24, 2025 Tempus AI, Inc. misses on earnings expectations. Reported EPS is $-0.18 EPS, expectations were $-0.15. Operator: Thank you for standing by. My name ...

EST Tempus AI (TEM) down 7% at $64.83 after Q4 earnings miss and guidanceDiscover the Best Stocks and Maximize Your Portfolio: See what ...

Would you like to be notified of the latest news and updates on the stock market?

Tempus posted a fourth-quarter adjusted net loss of $0.18 per share, $0.02 more per share than estimates by analysts surveyed by Visible Alpha. Revenue jumped 36% year-over-year to $200.7 million, but ...

The health care technology company posted revenue of $200.7 million in the period. For the year, the company reported a loss of $705.8 million, or $6.23 per share. Revenue was reported as $693.4 ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an emerging AI player in the healthcare field with a robust outlook ...